MX2019006552A - Terapia génica para mucopolisacaridosis de tipo i. - Google Patents
Terapia génica para mucopolisacaridosis de tipo i.Info
- Publication number
- MX2019006552A MX2019006552A MX2019006552A MX2019006552A MX2019006552A MX 2019006552 A MX2019006552 A MX 2019006552A MX 2019006552 A MX2019006552 A MX 2019006552A MX 2019006552 A MX2019006552 A MX 2019006552A MX 2019006552 A MX2019006552 A MX 2019006552A
- Authority
- MX
- Mexico
- Prior art keywords
- mucopolysaccharidosis
- type
- gene therapy
- methods
- provides compositions
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/16—Otologicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/24—Hydrolases (3) acting on glycosyl compounds (3.2)
- C12N9/2402—Hydrolases (3) acting on glycosyl compounds (3.2) hydrolysing O- and S- glycosyl compounds (3.2.1)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y302/00—Hydrolases acting on glycosyl compounds, i.e. glycosylases (3.2)
- C12Y302/01—Glycosidases, i.e. enzymes hydrolysing O- and S-glycosyl compounds (3.2.1)
- C12Y302/01076—L-Iduronidase (3.2.1.76)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/16011—Human Immunodeficiency Virus, HIV
- C12N2740/16041—Use of virus, viral particle or viral elements as a vector
- C12N2740/16043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
Abstract
La invención proporciona composiciones y métodos para el tratamiento de la MPS I.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201662430795P | 2016-12-06 | 2016-12-06 | |
PCT/US2017/064913 WO2018106807A1 (en) | 2016-12-06 | 2017-12-06 | Gene therapy for mucopolysaccharidosis, type i |
Publications (1)
Publication Number | Publication Date |
---|---|
MX2019006552A true MX2019006552A (es) | 2019-10-15 |
Family
ID=62491308
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2019006552A MX2019006552A (es) | 2016-12-06 | 2017-12-06 | Terapia génica para mucopolisacaridosis de tipo i. |
Country Status (13)
Country | Link |
---|---|
US (1) | US20220339296A1 (es) |
EP (1) | EP3551750A4 (es) |
JP (1) | JP2019536484A (es) |
KR (1) | KR20190089988A (es) |
CN (1) | CN110214182A (es) |
AU (1) | AU2017370662A1 (es) |
BR (1) | BR112019011635A2 (es) |
CA (1) | CA3046079A1 (es) |
IL (1) | IL267057A (es) |
MA (1) | MA47847A (es) |
MX (1) | MX2019006552A (es) |
RU (1) | RU2019120721A (es) |
WO (1) | WO2018106807A1 (es) |
Families Citing this family (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US11214789B2 (en) | 2016-05-03 | 2022-01-04 | Flodesign Sonics, Inc. | Concentration and washing of particles with acoustics |
AU2019315438A1 (en) * | 2018-07-30 | 2021-01-28 | Centro de Investigaciones Energeticas, Medioambientales Y Tecnologicas, O.A., M.P. | Methods for gene modification of hematopoietic cells |
CN115109790A (zh) * | 2021-03-23 | 2022-09-27 | 北京据德医药科技有限公司 | 一种重组a-L-艾杜糖醛酸普酶及其制备方法 |
WO2022258967A1 (en) * | 2021-06-08 | 2022-12-15 | Touchlight IP Limited | Lentiviral vector |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR2872170B1 (fr) * | 2004-06-25 | 2006-11-10 | Centre Nat Rech Scient Cnrse | Lentivirus non interactif et non replicatif, preparation et utilisations |
US20110294114A1 (en) * | 2009-12-04 | 2011-12-01 | Cincinnati Children's Hospital Medical Center | Optimization of determinants for successful genetic correction of diseases, mediated by hematopoietic stem cells |
US9789139B2 (en) * | 2011-06-10 | 2017-10-17 | Bluebird Bio, Inc. | Gene therapy vectors for adrenoleukodystrophy and adrenomyeloneuropathy |
WO2013175446A1 (en) * | 2012-05-25 | 2013-11-28 | Commissariat A L'energie Atomique Et Aux Energies Alternatives | Vector for the selective silencing of a gene in astrocytes |
WO2014201252A2 (en) * | 2013-06-13 | 2014-12-18 | Shire Human Genetic Therapies, Inc. | Messenger rna based viral production |
US11326183B2 (en) * | 2016-02-12 | 2022-05-10 | Bluebird Bio, Inc. | VCN enhancer compositions and methods of using the same |
-
2017
- 2017-12-06 KR KR1020197019344A patent/KR20190089988A/ko not_active Application Discontinuation
- 2017-12-06 EP EP17877511.0A patent/EP3551750A4/en not_active Withdrawn
- 2017-12-06 MX MX2019006552A patent/MX2019006552A/es unknown
- 2017-12-06 WO PCT/US2017/064913 patent/WO2018106807A1/en unknown
- 2017-12-06 CN CN201780083351.5A patent/CN110214182A/zh active Pending
- 2017-12-06 CA CA3046079A patent/CA3046079A1/en not_active Abandoned
- 2017-12-06 AU AU2017370662A patent/AU2017370662A1/en not_active Abandoned
- 2017-12-06 BR BR112019011635-4A patent/BR112019011635A2/pt not_active IP Right Cessation
- 2017-12-06 JP JP2019551256A patent/JP2019536484A/ja active Pending
- 2017-12-06 MA MA047847A patent/MA47847A/fr unknown
- 2017-12-06 RU RU2019120721A patent/RU2019120721A/ru not_active Application Discontinuation
- 2017-12-06 US US16/466,130 patent/US20220339296A1/en not_active Abandoned
-
2019
- 2019-06-03 IL IL267057A patent/IL267057A/en unknown
Also Published As
Publication number | Publication date |
---|---|
IL267057A (en) | 2019-08-29 |
BR112019011635A2 (pt) | 2019-11-12 |
CN110214182A (zh) | 2019-09-06 |
RU2019120721A (ru) | 2021-01-11 |
CA3046079A1 (en) | 2018-06-14 |
MA47847A (fr) | 2020-01-29 |
AU2017370662A1 (en) | 2019-06-27 |
EP3551750A4 (en) | 2020-07-22 |
KR20190089988A (ko) | 2019-07-31 |
WO2018106807A1 (en) | 2018-06-14 |
JP2019536484A (ja) | 2019-12-19 |
US20220339296A1 (en) | 2022-10-27 |
EP3551750A1 (en) | 2019-10-16 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MX2021000710A (es) | Composiciones que comprenden cepas bacterianas. | |
MX2019007030A (es) | Composiciones y metodos para el tratamiento del cancer. | |
MX2021000077A (es) | Composiciones que comprenden cepas bacterianas. | |
MX2019003623A (es) | Composiciones y metodos para el tratamiento de afecciones oftalmicas. | |
MX2018015761A (es) | Composiciones que comprenden cepas bacterianas. | |
MD3209381T2 (ro) | Compoziții care conțin tulpini bacteriene | |
MX2018006239A (es) | Composiciones que comprenden cepas bacterianas. | |
MX2018006398A (es) | Composiciones que comprenden cepas bacterianas. | |
MX2017016529A (es) | Composiciones que comprenden cepas bacterianas. | |
MX2017016564A (es) | Composiciones que comprenden cepas bacterianas. | |
PH12017501999A1 (en) | K-ras modulators | |
MX2017016560A (es) | Composiciones que comprenden cepas bacterianas. | |
MX2017016525A (es) | Composiciones que comprenden cepas bacterianas. | |
MX2018009750A (es) | Composiciones potenciadoras de vcn y métodos para su uso. | |
MX2018016038A (es) | Compuestos y metodos para modular la funcion del acido ribonucleico (arn). | |
AU2019268074A1 (en) | Methods for treating hepcidin-mediated disorders | |
MX2018016057A (es) | Composiciones y metodos para tratar enfermedades cardiovasculares. | |
MX2022000053A (es) | Moduladores de interaccion de sestrina-gator2 y sus usos. | |
MX2018000715A (es) | Metodos para tratar cancer usando apilimod. | |
MX2018006700A (es) | Inhibidores aza-bencimidazol de peptidilarginina desiminasa (pad4). | |
PH12017501028A1 (en) | Treatment of retinal degeneration using progenitor cells | |
MX2019006552A (es) | Terapia génica para mucopolisacaridosis de tipo i. | |
IL251616B (en) | Methods and compounds for the treatment and prevention of muscle mass loss | |
MX2020006297A (es) | Variantes de cd19. | |
PH12017501864A1 (en) | Compositions and methods for treating autism |